Heart Disease Trial, Recruiting NCT03951311 Sponsor: Ruijin Hospital Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT03951311
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 14 years of age or older
  • People who have typical heart failure symptoms as measured by a standard medical checklist called the Framingham criteria
  • People whose heart pumps less efficiently than normal (specifically, where the heart's pumping function is below 50%), confirmed by a heart ultrasound or heart MRI, along with changes in the heart's structure or function and/or elevated levels of a specific heart stress marker in the blood

Who may not be able to join:

  • People who are younger than 14 or aged 90 or older
  • People who are pregnant
  • People who have cancer with a life expectancy of less than one year
  • People who are currently participating in another clinical trial
  • People who have an infection of the heart's inner lining (endocarditis), diseases affecting the sac around the heart (pericardial diseases), or heart defects present from birth
  • People whose heart failure is caused by a condition outside the heart itself, such as a lung condition, infection, metabolic problems, severe anaemia, blood poisoning, or abnormal connections between blood vessels
  • People who have not given their informed consent to participate
  • People who are unwilling to accept the treatments or procedures recommended by medical guidelines for their condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhijun Wu, MD, Ruijin Hospital

Phone: 008613818908053

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 June 2016
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

a composite of cardiovascular mortality or hospitalization due to subjectively and objectively worsening HF

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov